Studies find Botox cuts migraine days; Abbott to buy Evalve for up to $410M;

> Botox, the popular wrinkle-smoother sold by Allergan, significantly reduced the number of headache days for adults suffering from chronic migraines, according to two late-stage trials. Report [1]

> Abbott Laboratories agreed to buy surgery-device maker Evalve for up to $410 million, broadening its reach in the emerging market for minimally invasive heart repair. Report [2]

> Daiichi Sankyo hired former Novartis senior vice president Yugal Sikri to be the new India CEO of subsidiary Ranbaxy Laboratories, the India Times says. Report [3]

> Reckitt Benckiser's Suboxone heroin-dependency treatment will probably cope better with generic competition than the company forecasts, meaning profit estimates are too low, according to investors and analysts. Report [4]

> Eli Lilly said new data showed that patients with chronic low back pain on Cymbalta maintained reductions in pain for 41 weeks. Report [5]

> Par Pharmaceutical got the FDA nod to market nateglinide, a generic version of Novartis' diabetes drug Starlix. Report [6]

> India's Glenmark Pharmaceuticals reportedly raised 4.13 billion rupees ($85 million) from a share sale to institutional investors. Report [7]

> Morgan Stanley analysts initiated coverage of Pfizer with a $19 price target and an "overweight" rating. Report [8]

Biotech News

> In what is being hailed as a first for an Australian biotech company, Chemgenex has filed for FDA approval of a new cancer therapy. Article [9]

> pooked by signs of elevated liver enzyme levels, Merck announced today that it is dumping its development program for the acute migraine therapy MK-3207. But it touted promising results for a separate migraine drug now in late-stage tests. Article [10]

> The Dutch antibody developer arGEN-X has garnered $13.6 million in a Series A, which will be used to develop its antibody platform and create a slate of mAb candidates for development. Article [11]

> The private Swiss developer Evolva has swooped in to merge with the troubled biotech Arpida, which saw its share price all but erased after its lead drug program--for intravenous antibiotic iclaprim--failed to gain regulatory approval. Article [12]

> Complete Genomics has pulled off the feat of sequencing 14 full human genomes for a group of customers in the medical research field at a fraction of the old cost. Article [13]

And Finally... Pandemic swine flu can infect cells deeper in the lungs than seasonal flu can, according to a new study published today in Nature Biotechnology. Release [14]